Please login to the form below
GSK trials shingles vaccine
GlaxoSmithKline has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles
GlaxoSmithKline (GSK) has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles.
The phase III clinical programme will study more than 30,000 patients worldwide and will evaluate the efficacy, safety and immunogenicity of the vaccine.
Norman Begg, chief medical officer of GSK Biologicals said: "The commencement of the phase III programme for our candidate's herpes zoster vaccine is a significant milestone. Shingles is an often debilitating condition for which there are limited treatment and prevention options.
"Progression into late-stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need," he added.
Herpes zoster is commonly known as shingles. It is caused by the varicella-zoster virus (VZV) and occurs in around 3 out of 1,000 people per year in Europe.
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Account Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Business Director
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
